BackgroundSeveral influential aspects of survey research have been under-investigated and there is a lack of guidance on reporting survey studies, especially web-based projects. In this review, we aim to investigate the reporting practices and quality of both web- and non-web-based survey studies to enhance the quality of reporting medical evidence that is derived from survey studies and to maximize the efficiency of its consumption.MethodsReporting practices and quality of 100 random web- and 100 random non-web-based articles published from 2004 to 2016 were assessed using the SUrvey Reporting GuidelinE (SURGE). The CHERRIES guideline was also used to assess the reporting quality of Web-based studies.ResultsOur results revealed a potential gap in the reporting of many necessary checklist items in both web-based and non-web-based survey studies including development, description and testing of the questionnaire, the advertisement and administration of the questionnaire, sample representativeness and response rates, incentives, informed consent, and methods of statistical analysis.ConclusionOur findings confirm the presence of major discrepancies in reporting results of survey-based studies. This can be attributed to the lack of availability of updated universal checklists for quality of reporting standards. We have summarized our findings in a table that may serve as a roadmap for future guidelines and checklists, which will hopefully include all types and all aspects of survey research.

No abstract

緒 言 Despite significant advances in the prevention and treatment of malaria, it remains to be one of the calamitous global health and socioeconomic concern. Several drugs are currently available for malaria treatment, however parasites began to develop resistance against most of these drugs including the first line drug, Artemisinin. A newly approved vaccine, RTS, S, has raised hope for preventive therapy, yet suffered with limited efficacy (shorter and stage-specific immunity). As a result, look for new small molecule drug candidates with novel target/mechanism of action has become pivotal. There are various phenotypic screening methods to identify novel antimalarials, however, most of them are time-consuming, costly and laborious. In contrary, in silico approach found to be effective to screen millions of compounds comparatively at shorter time and less expensive way than conventional screening. Therefore, in this study, we developed new prediction models for in silico antimalarial compound screening based on the physicochemical properties of small chemical compounds (hemozoin inhibitors) identified from our previous study. 対象と方法In this study, 224 positive hemozoin inhibitors (obtained from our previous study), were tested for in vitro erythrocytic antimalarial activity against chloroquine -mefloquine sensitive Plasmodium falciparum strain, 3D7A and their antihemozoin activity. The physicochemical properties of the active compounds (antimalarials and hemozoin inhibitors) were extracted from ChemSpider and SciFinder databases. To develop the model, univariable logistic regression was performed to examine the association between physicochemical properties (variables) and antimalarial activity of the compounds (outcome). Subsequently, to find independent predictors, variables P<0.1 and/or significant variables in previous study, were subjected to multivariable analysis using Bayesian model averaging (BMA) based on the Bayesian information criterion (BIC), where the smaller BIC value indicates the better model. The data were randomly divided into two sets -training and testing, with a ratio of 70:30. The BMA models were developed using training set and validated by testing data set. The data were analysed by using RStudio 1.0.44

Ginsenoside Rk1 (G-Rk1) is a unique component created by processing the ginseng plant (mainly Sung Ginseng (SG)) at high temperatures. The aim of our study was to systematically review the pharmacological effects of G-Rk1. We utilized and manually searched eight databases to select in vivo and in vitro original studies that provided information about biological, pharmaceutical effects of G-Rk1 and were published up to July 2017 with no restriction on language or study design. Out of the 156 papers identified, we retrieved 28 eligible papers in the first skimming phase of research. Several articles largely described the G-Rk1 anti-cancer activity investigating “cell viability”, “cell proliferation inhibition”, “apoptotic activity”, and “effects of G-Rk1 on G1 phase and autophagy in tumor cells” either alone or in combination with G-Rg5. Others proved that it has antiplatelet aggregation activities, anti-inflammatory effects, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis. In conclusion, G-Rk1 has a significant anti-tumor effect on liver cancer, melanoma, lung cancer, cervical cancer, colon cancer, pancreatic cancer, gastric cancer, and breast adenocarcinoma against in vitro cell lines. In vivo experiments are further warranted to confirm these effects.

No abstract